Suzhou Ribo Life Science (6938) Announces Phase III Clinical Trial Launch for RBD7022 Injection in China

Bulletin Express

Mar 02

Suzhou Ribo Life Science Co., Ltd. (6938) announced that RBD7022 Injection, independently developed by the Group, will begin a Phase III clinical trial after completing public registration by collaborator Qilu Pharmaceutical Co., Ltd. The investigational siRNA drug targets PCSK9, an enzyme closely associated with controlling low-density lipoprotein (LDL) cholesterol levels.

In December 2023, exclusive rights to develop, manufacture, and commercialize RBD7022 Injection in Chinese mainland, Hong Kong, and Macau were granted to Qilu Pharmaceutical. The product may not ultimately achieve successful development or commercialization, so shareholders and potential investors are advised to exercise caution when dealing in the shares of Suzhou Ribo Life Science Co., Ltd. (6938).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1108221887"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108221887\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108221887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 09:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108221887","market":"hk","top_or_hot":-1,"title":"Suzhou Ribo Life Science (6938) Announces Phase III Clinical Trial Launch for RBD7022 Injection in China","media":"Bulletin Express","content":"<p>Suzhou Ribo Life Science Co., Ltd. (6938) announced that RBD7022 Injection, independently developed by the Group, will begin a Phase III clinical trial after completing public registration by collaborator Qilu Pharmaceutical Co., Ltd. The investigational siRNA drug targets PCSK9, an enzyme closely associated with controlling low-density lipoprotein (LDL) cholesterol levels.</p>\n<p>In December 2023, exclusive rights to develop, manufacture, and commercialize RBD7022 Injection in Chinese mainland, Hong Kong, and Macau were granted to Qilu Pharmaceutical. The product may not ultimately achieve successful development or commercialization, so shareholders and potential investors are advised to exercise caution when dealing in the shares of Suzhou Ribo Life Science Co., Ltd. (6938).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Suzhou Ribo Life Science (6938) Announces Phase III Clinical Trial Launch for RBD7022 Injection in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSuzhou Ribo Life Science (6938) Announces Phase III Clinical Trial Launch for RBD7022 Injection in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-02 09:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Suzhou Ribo Life Science Co., Ltd. (6938) announced that RBD7022 Injection, independently developed by the Group, will begin a Phase III clinical trial after completing public registration by collaborator Qilu Pharmaceutical Co., Ltd. The investigational siRNA drug targets PCSK9, an enzyme closely associated with controlling low-density lipoprotein (LDL) cholesterol levels.</p>\n<p>In December 2023, exclusive rights to develop, manufacture, and commercialize RBD7022 Injection in Chinese mainland, Hong Kong, and Macau were granted to Qilu Pharmaceutical. The product may not ultimately achieve successful development or commercialization, so shareholders and potential investors are advised to exercise caution when dealing in the shares of Suzhou Ribo Life Science Co., Ltd. (6938).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"","article_id":"1108221887","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108221887","pubTimestamp":1772414532,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Suzhou Ribo Life Science Co., Ltd. (6938) announced that RBD7022 Injection, independently developed by the Group, will begin a Phase III clinical trial after completing public registration by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B"},"translate_title":"苏州日博生命科学（6938）宣布RBD7022注射液在中国开展III期临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"Suzhou Ribo Life Science Co., Ltd. (6938) announced that RBD7022 Injection, independently developed by the Group, will begin a Phase III clinical trial after completing public registration by collaborator Qilu Pharmaceutical Co., Ltd. The investigational siRNA drug targets PCSK9, an enzyme closely associated with controlling low-density lipoprotein (LDL) cholesterol levels.\nIn December 2023, exclusive rights to develop, manufacture, and commercialize RBD7022 Injection in Chinese mainland, Hong Kong, and Macau were granted to Qilu Pharmaceutical. The product may not ultimately achieve successful development or commercialization, so shareholders and potential investors are advised to exercise caution when dealing in the shares of Suzhou Ribo Life Science Co., Ltd. (6938).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}